Transjugular Intrahepatic Portosystemic Shunt (Tips) for the Management of Refractory Ascites in Cirrhosis

Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and Treatment: Second Edition

Volumn , Issue , 2007, Pages 251-259

  Garcia Tsao, Guadalupe ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ascites; Cirrhosis; Hepatorenal syndrome (HRS); Peripheral vasodilation; Sinusoidal hypertension

Indexed keywords

EID: 30344475292     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987476.ch20     Document Type: Chapter

References (57)

1. Arroyo V, Ginès P, Gerbes AL et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23:164-76.
2. Rector WG. Portal hypertension: a permissive factor only in the development of ascites and variceal bleeding. Liver 1986; 6:221-6.
3. Morali GA, Sniderman KW, Deitel KM et al. Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites? J Hepatol 1992; 16:249-50.
4. Villanueva C, Minana J, Ortiz J et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001; 345:647-55.
5. Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodés J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003; 37:902-8.
6. Casado M, Bosch J, Garcia-Pagan JC et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998; 114:1296-303.
7. Castells A, Saló J, Planas R et al. Impact of shunt surgery for variceal bleeding in the natural history of ascites in cirrhosis: a retrospective study. Hepatology 1994; 20:584-91.
8. Voorhees ABJ, Price JBJ, Britton RC. Portosystemic shunting procedures for portal hypertension. Twenty-six year experience in adults with cirrhosis of the liver. Am J Surg 1970; 119:501-5.
9. Orloff MJ, Orloff MS, Orloff SL, Girard B. Experimental, clinical, and metabolic results of side-to-side portacaval shunt for intractable cirrhotic ascites. J Am Coll Surg 1997; 183:557-70.
10. Franco D, Vons C, Traynor O, De Smadja C. Should portosystemic shunt be reconsidered in the treatment of intractable ascites in cirrhosis? Arch Surg 1988; 123:987-91.
11. Rosch J, Uchida BT, Putnam JS, Buschman RW, Law RD, Hershey AL. Experimental intrahepatic portacaval anastomosis: use of expandable gianturco stents. Radiology 1987; 162:481-5.
12. Luca A, D'Amico G, LaGalla R, Midiri M, Morabito A, Pagliaro L. TIPS for prevention of recurrent bleeding in patients with cirrhosis: meta-analysis of randomized clinical trials. Radiology 1999; 212:411-21.
13. Papatheodoridis GV, Goulis J, Leandro G, Patch D, Burroughs AK. Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding. A meta-analysis. Hepatology 1999; 30:612-22.
14. Burroughs AK, Vangeli M. Transjugular intrahepatic portosystemic shunt versus endoscopic therapy: randomized trials for secondary prophylaxis of variceal bleeding: an updated meta-analysis. Scand J Gastroenterol 2002; 37:249-52.
15. Wong F, Sniderman K, Liu P, Allidina Y, Sherman M, Blendis L. Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med 1995; 122:816-22.
16. Wong F, Sniderman K, Liu P, Blendis L. The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt. Gastroenterology 1997; 112:899-907.
17. Gerbes AL, Gulberg V, Waggershauser T, Holl J, Reiser M. Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites or without ascites. Hepatology 1998; 28:683-8.
18. Lebrec D, Giuily N, Hadengue A et al. and a French Group of Clinicans and a Group of Biologists. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. J Hepatol 1996; 25:135-44.
19. Somberg KA, Lake JR, Tomlanovich SJ, LaBerge JM, Feldstein V, Bass NM. Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function. Hepatology 1995; 21:709-16.
20. Quiroga J, Sangro B, Nunez M et al. Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters. Hepatology 1995; 21:986-94.
21. Wong W, Liu P, Blendis L, Wong F. Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites. Am J Med 1999; 106:315-22.
22. Zemel G, Katzen B, Becker GJ, Benenati JF, Sallee S. Percutaneous transjugular portosystemic shunt. J Am Med Assoc 1991; 266:390-3.
23. LaBerge JM, Ring EJ, Gordon RL et al. Creation of transjugular intrahepatic porto-systemic shunts with the Wallstent endoprosthesis: results in 100 patients. Radiology 1993; 187:413-20.
24. Ferral H, Bjarnason H, Wegryn SA et al. Refractory ascites: early experience in treatment with transjugular intrahepatic portosystemic shunt. Radiology 1993; 189:795-801.
25. Russo MW, Sood A, Jacobson IM, Brown RS. Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality. Am J Gastroenterol 2003; 98:2521-7.
26. Ochs A, Rossle M, Haag K et al. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 1995; 332:1192-7.
27. Crenshaw WB, Gordon FD, McEniff NJ et al. Severe ascites: efficacy of the transjugular intrahepatic portosystemic shunt in treatment. Radiology 1996; 200:185-92.
28. Martinet JP, Fenyves D, Legault L et al. Treatment of refractory ascites using transjugular intrahepatic portosystemic shunt (TIPS). A caution. Dig Dis Sci 1997; 42:161-6.
29. Nazarian GK, Bjarnason H, Dietz CAJ et al. Refractory ascites: midterm results of treatment with a transjugular intrahepatic portosystemic shunt. Radiology 1997; 205:173-80.
30. Deschenes M, Dufresne MP, Bui B et al. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites. Am J Gastroenterol 1999; 94:1361-5.
31. Peron JM, Barange K, Otal P et al. Transjugular intrahepatic portosystemic shunts in the treatment of refractory ascites: results in 48 consecutive patients. J Vasc Interv Radiol 2000; 11:1211-16.
32. Boyer TD. Transjugular intrahepatic portosystemic shunt: current status. Gastroenterology 2003; 124:1700-10.
33. Trotter JF, Suhocki PV. Incarceration of umbilical hernia following transjugular intrahepatic portosystemic shunt for the treatment of ascites. Liver Transpl Surg 1999; 5:209-10.
34. Ginès P, Arroyo V, Vargas V et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med 1991; 325:829-35.
35. Ginès A, Planas R, Angeli P et al. Treatment of patients with cirrhosis and refractory ascites by LeVeen shunt with titanium tip. Comparison with therapeutic paracentesis. Hepatology 1995; 22:124-31.
36. Rossle M, Ochs A, Gulberg V et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342:1701-7.
37. Ginès P, Uriz J, Calahorra B et al., for the International Study Group on Refractory Ascites in Cirrhosis. Transjugular intrahepatic portosystemic shunting versus repeated paracentesis plus intravenous albumin for refractory ascites in cirrhosis: a multicenter randomized comparative study. Gastroenterology 2002; 123:1839-47.
38. Sanyal AJ, Genning C, Reddy KR et al., North American Study for the Treatment of Refractory Ascites Group. The North American Study for the Treatment of Refractory Ascites. Gastroenterology 2003; 124:634-41.
39. Arroyo V, Rodés J, Gutiérrez Lizárraga MA, Revert L. Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. Am J Dig Dis 1976; 21:249-56.
40. Llach J, Ginès P, Arroyo V et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94:482-7.
41. Schepke M, Roth F, Koch L et al. Prognostic impact of renal impairment and sodium imbalance in patients undergoing transjugular intrahepatic portosystemic shunting for the prevention of variceal rebleeding. Digestion 2003; 67:146-53.
42. Allard JP, Chau J, Sandokji K, Blendis LM, Wong F. Effects of ascites resolution after successful TIPS on nutrition in cirrhotic patients with refractory ascites. Am J Gastroenterol 2001; 96:2442-7.
43. Gulberg V, Liss I, Bilzer M, Waggershauser T, Reiser M, Gerbes AL. Improved quality of life in patients with refractory or recidivant ascites after insertion of transjugular intrahepatic portosystemic shunts. Digestion 2002; 66:127-30.
44. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, TerBorg PCJ. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31:864-71.
45. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33:464-70.
46. Chalasani N, Clark WS, Martin LG et al. Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting. Gastroenterology 2000; 118:138-44.
47. Salerno F, Merli M, Cazzaniga M et al. MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. J Hepatol 2002; 36:494-500.
48. Schepke M, Roth F, Fimmers R et al. Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting. Am J Gastroenterol 2003; 98:1167-74.
49. Angermayr B, Cejna M, Karnel F et al. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut 2003; 52:879-85.
50. Strauss RM, Martin LG, Kaufman SL, Boyer TD. Transjugular intrahepatic portal systemic shunt for the management of symptomatic cirrhotic hydrothorax. Am J Gastroenterol 1994; 89:1522.
51. Gordon FD, Anastopoulos HT, Crenshaw W et al. The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt. Hepatology 1997; 25:1366-9.
52. Jeffries MA, Kazanjian S, Wilson M, Punch J, Fontana RJ. Transjugular intrahepatic portosystemic shunts and liver transplantation in patients with refractory hepatic hydrothorax. Liver Transplant Surg 1998; 4:416-23.
53. Siegerstetter V, Deibert P, Ochs A, Olschewski M, Blum HE, Rossle M. Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40 patients. Eur J Gastroenterol Hepatol 2001; 13:529-34.
54. Spencer EB, Cohen DT, Darcy MD. Safety and efficacy of transjugular intrahepatic portosystemic shunt creation for the treatment of hepatic hydrothorax. J Vasc Interv Radiol 2002; 13:385-90.
55. Moore KP, Wong F, Ginès P et al. The management of ascites in cirrhosis: report on the Consensus Conference of the International Ascites Club. Hepatology 2003; 38:258-66.
56. Angermayr B, Cejna M, Koenig F, Karnel F, Gangl A, Peck-Radosavljevic M, for the Vienna TIPS Study Group. Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. Hepatology 2003; 38:1043-50.
57. Salerno F, Merli M, Riggio O et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004; 40(3):629-35.